RT Journal Article
SR Electronic
T1 Development and external validation of a logistic regression derived formula based on repeated routine hematological measurements predicting survival of hospitalized Covid-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.20.20248563
DO 10.1101/2020.12.20.20248563
A1 Stefan Heber
A1 David Pereyra
A1 Waltraud C. Schrottmaier
A1 Kerstin Kammerer
A1 Jonas Santol
A1 Erich Pawelka
A1 Markus Hana
A1 Alexander Scholz
A1 Markus Liu
A1 Agnes Hell
A1 Klara Heiplik
A1 Benno Lickefett
A1 Sebastian Havervall
A1 Marianna T. Traugott
A1 Matthias Neuböck
A1 Christian Schörgenhofer
A1 Tamara Seitz
A1 Christa Firbas
A1 Mario Karolyi
A1 Günter Weiss
A1 Bernd Jilma
A1 Charlotte Thålin
A1 Rosa Bellmann-Weiler
A1 Helmut J.F. Salzer
A1 Michael J.M. Fischer
A1 Alexander Zoufaly
A1 Alice Assinger
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.20.20248563.abstract
AB Background The Covid-19 pandemic has become a global public health crisis and providing optimal patient care while preventing a collapse of the health care system is a principal objective worldwide.Objective To develop and validate a prognostic model based on routine hematological parameters to predict uncomplicated disease progression to support the decision for an earlier discharge.Design Development and refinement of a multivariable logistic regression model with subsequent external validation. The time course of several hematological variables until four days after admission were used as predictors. Variables were first selected based on subject matter knowledge; their number was further reduced using likelihood ratio-based backward elimination in random bootstrap samples.Setting Model development based on three Austrian hospitals, validation cohorts from two Austrian and one Swedish hospital.Participants Model development based on 363 survivors and 78 non-survivors of Covid-19 hospitalized in Austria. External validation based on 492 survivors and 61 non-survivors hospitalized in Austria and Sweden.Outcome In-hospital death.Main Results The final model includes age, fever upon admission, parameters derived from C-reactive protein (CRP) concentration, platelet count and creatinine concentration, approximating their baseline values (CRP, creatinine) and change over time (CRP, platelet count). In Austrian validation cohorts both discrimination and calibration of this model were good, with c indices of 0.93 (95% CI 0.90 - 0.96) in a cohort from Vienna and 0.93 (0.88 - 0.98) in one from Linz. The model performance seems independent of how long symptoms persisted before admission. In a small Swedish validation cohort, the model performance was poorer (p = 0.008) compared with Austrian cohorts with a c index of 0.77 (0.67 - 0.88), potentially due to substantial differences in patient demographics and clinical routine.Conclusions Here we describe a formula, requiring only variables routinely acquired in hospitals, which allows to estimate death probabilities of hospitalized patients with Covid-19. The model could be used as a decision support for earlier discharge of low-risk patients to reduce the burden on the health care system. The model could further be used to monitor whether patients should be admitted to hospital in countries with health care systems with emphasis on outpatient care (e.g. Sweden).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is no interventional trial and is therefore not registered at ClinicalTrials.govFunding StatementThis work is part of the ACOVACT study of the Medical University of Vienna and is financially supported by the Austrian Federal Ministry of Education, Science and Research, the Medical-Scientific Fund of the Mayor of Vienna (COVID024) and the Austrian Science Fund (P32064; SFB-54).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The recovery of data at the Clinic Favoriten in Vienna is part of the ACOVACT study (ClinicalTrials.gov NCT04351724) approved by the local ethics committee (EK1315/2020), which aims to compare the effect of different antiviral and adjunctive treatments on outcome of hospitalized Covid-19 patients. This study was further approved by the ethics committee of the Innsbruck Medical University (ID of ethical vote: 1167/2020) and the Stockholm Ethical Review Board (COMMUNITY study dnr 2020-01653)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll original data will be made available upon request.